臨床神経学

第51回日本神経学会総会

<シンポジウム11―4>脳梗塞臨床の第一線における問題点:Branch atheromatous disease(BAD)をどう考え,どう対処するか
BADをどう治療するか

武田 英孝1), 高木 誠2), 山本 康正3), J-BAD Investigators4)

1)埼玉医科大学国際医療センター神経内科・脳卒中内科〔〒350―1298 埼玉県日高市山根1397―1〕
2)東京都済生会中央病院神経内科
3)京都第二赤十字病院
4)J-BAD Registry

Branch atheromatous disease (BAD) has been recognized as one of the types of stroke which is often associated with clinical deterioration. Coagulation and platelet activation should play an important role in early neurological progression of BAD, which include complicated aspects for understanding the pathophysiology and the treatment. It has been suggested that multidrug combination therapy involving antiplatelet and anticoagulation could not prevent worsening of symptoms in the acute stage of BAD: nevertheless it should be important to improve prognosis of patients in the chronic stage. Further investigation including randomized controlled study will be needed for the accumulation of various evidences.
Full Text of this Article in Japanese PDF (381K)

(臨床神経, 50:921−924, 2010)
key words:分枝粥腫病,微小アテローム,多剤カクテル療法,白質傷害

(受付日:2010年5月22日)